Impacto del Índice neutrófilo/linfocito en el Melanoma Lentiginoso Acral: Impact of Neutrophil-Lymphocyte Ratio in Acral Lentiginous melanoma

Joseph Alburqueque-Melgarejo; Martha Eugenia  Aguirre Coronado; Brady  Beltrán Gárate

doi:10.25176/RFMH.v24i3.6679

Authors

Joseph Alburqueque-Melgarejo Scientific University of the South, Lima, Peru
Martha Eugenia Aguirre Coronado Jose Casimiro Ulloa Emergency Hospital, Lima, Peru
Brady Beltrán Gárate Biomedical Sciences Research Institute, Faculty of Human Medicine, Ricardo Palma University, Lima, Peru

DOI:

https://doi.org/10.25176/RFMH.v24i3.6679

Keywords:

Acral Lentiginous melanoma, Prognostic factor, Survival, Neutrophil-Lymphocyte Ratio

Abstract

Introduction: Acral lentiginous melanoma (ALM) is the fourth type of cutaneous melanoma and is the most common subtype in some countries in Latin America and Asia. The neutrophil-lymphocyte ratio (NLR) is an inflammatory marker that has been shown to be useful as a prognostic tool in several malignant neoplasms.

Objective: The objective of the study was to evaluate whether NLR has prognostic value in ALM. A retrospective study was conducted that included patients with ALM between 2010 and 2015.

Methods: An observational, analytical and retrospective cohort design was used. We worked with a total population of 69 patients with the diagnosis of acral lentiginous melanoma. For the statistical analysis, the SPSS statistical package version 26 was used. Univariate and multivariate Cox proportional regression models were performed.

Results: A total of 69 patients with ALM were included. The median age was 68 years, with a predominance of females (55%). Most patients had T4 (34%), lymph node involvement (57.1%), and Clark III (34.4%). In univariate analysis, Clark level III/IV, anaplasia, lymphocytic infiltration, stage III-IV, and NLR were associated with prognoses. In the multivariate analysis, NLR >3.5 (HR 3.9, 95% CI 1.5-10.3, p=0.005) and Clark level III-IV (HR 3.5, 95% CI 1 .6-7.8, p= 0.002) were associated with poor overall survival (OS).

Conclusions: NLR is an independent prognostic factor for survival in ALM.

Downloads

Download data is not yet available.

Author Biographies

Joseph Alburqueque-Melgarejo, Scientific University of the South, Lima, Peru

Master in Medicine

Martha Eugenia Aguirre Coronado , Jose Casimiro Ulloa Emergency Hospital, Lima, Peru

Internal Medicine

Brady Beltrán Gárate, Biomedical Sciences Research Institute, Faculty of Human Medicine, Ricardo Palma University, Lima, Peru

Medical Oncologist

References

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R,

Hauschild A, et al. Melanoma. The Lancet. 2018; 392(10151):971-984. doi:

1016/S0140-6736(18)31559-9.

The Global Cancer Observatory. All Cancers Globocan 2018. Globocan.

;876:1–2. Disponible en: https://gco.iarc.fr/en

Geller AC, Annas GD. Epidemiology of melanoma and nonmelanoma skin

cancer. Semin Oncol Nurs. 2003;19(1):2–11. doi:

1053/sonu.2003.50000.

Krausz K. Pathology of Melanocytic Disorders. Pathology of Melanocytic

Disorders 2ed. 2012.

Lv J, Dai B, Kong Y, Shen X, Kong J. Acral melanoma in Chinese: A

clinicopathological and prognostic study of 142 cases. Sci Rep.

;6:31432. doi: 10.1038/srep31432

Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral

lentiginous melanoma: A clinicoprognostic study of 126 cases. Br J

Dermatol. 2006;155(3):561–9. doi: 10.1111/j.1365-2133.2006.07368.x.

Jung HJ, Kweon S-S, Lee J-B, Lee S-C, Yun SJ. A Clinicopathologic

Analysis of 177 Acral Melanomas in Koreans. JAMA Dermatology.

;149(11):1281-8. doi: 10.1001/jamadermatol.2013.5853.

Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, et al.

Early detection of acral melanoma: A review of clinical, dermoscopic,

histopathologic, and molecular characteristics. J Am Acad Dermatol.

;81(3):805–12. doi: 10.1016/j.jaad.2019.01.081.

Asgari MM, Shen L, Sokil MM, Yeh I, Jorgenson E. Prognostic factors and

survival in acral lentiginous melanoma. Br J Dermatol. 2017;177(2):428–35.

doi: 10.1111/bjd.15600.

Beltrán B, Paredes S, Cotrina E, Sotomayor E, Castillo JJ. The impact of the

neutrophil : lymphocyte ratio in response and survival of patients with de

novo diffuse large B-cell lymphoma. Leuk Res. 2018;67:82–5. doi:

1016/j.leukres.2018.02.011.

Beltran BE, Aguilar C, Quiñones P, Morales D, Chavez JC, Sotomayor EM,

et al. The neutrophil-to-lymphocyte ratio is an independent prognostic factor

in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma.

;57(1):58–62. doi: 10.3109/10428194.2015.1045897.

STROBE. Checklists – STROBE. 2023. Disponible en: https://www.strobe-

statement.org/checklists/

Vano Y, Stéphane Oudard, By MA, Tetu P, Thibault C, Hail Aboudagga, et

al. Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A

prospective cohort study in metastatic cancer patients. PLOS ONE. 2018

Apr 6;13(4):e0195042–2. doi: 10.1371/journal.pone.0195042

Castaneda CA, Torres-Cabala C, Castillo M, Villegas V, Casavilca S, Cano L, et al.

Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large

cohort of cases from Latin America. Clin Transl Oncol. 2017;19(12):1478–88. doi:

1007/s12094-017-1685-3.

Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline

neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint

inhibitors: A review and meta-analysis. OncoTargets and Therapy. 2018. 11:

p. 955–65. doi: 10.2147/OTT.S153290.

Ding Y, Zhang S, Qiao J. Prognostic value of neutrophil-to-lymphocyte ratio

in melanoma: Evidence from a PRISMA-compliant meta-analysis. Med

(United States). 2018;97(30):1–7. doi: 10.1097/MD.0000000000011446

Zhan H, Ma JY, Jian QC. Prognostic significance of pretreatment neutrophil-

to-lymphocyte ratio in melanoma patients: A meta-analysis. Clin Chim Acta.

;484:136–40. doi: 10.1016/j.cca.2018.05.055.

Cocorocchio E, Martinoli C, Gandini S, Pala L, Conforti F, Stucchi S, et al.

Baseline neutrophil‑to‑lymphocyte ratio (NLR) is associated with outcome of

patients treated with BRAF inhibitors. Clin Transl Oncol. 2020; 22(10):1818-

doi: 10.1007/s12094-020-02320-y.

Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Jessica JM, Postow MA,

et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment

failure and death in patients who have melanoma treated with PD-1 inhibitor

monotherapy. Cancer. 2020;126(1):76–85. doi: 10.1002/cncr.32506.

Wade RG, Robinson A V., Lo MCI, Keeble C, Marples M, Dewar DJ, et al.

Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as

Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort

Study. Ann Surg Oncol. 2018;25(11):3341–9. doi: 10.1245/s10434-018-

-x.

Davis JL, Langan RC, Panageas KS, Zheng J, Postow MA, Brady MS, et al.

Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available

Biomarker Associated with Death due to Disease in High Risk

Nonmetastatic Melanoma. Ann Surg Oncol. 2017;24(7):1989–96. doi:

1245/s10434-017-5836-0.

Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D,

et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of

ipilimumab-treated metastatic melanoma patients. Br J Cancer.

;112(12):1904–10. doi: 10.1038/bjc.2015.180.

Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et

al. Neutrophil to Lymphocyte Ratio is Associated With Outcome During

Ipilimumab Treatment. EBioMedicine. 2017;18:56–61. doi:

1016/j.ebiom.2017.03.029.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C,

et al. Prognostic and predictive value of the immune infiltrate in cancer.

Oncoimmunology. 2012. 1(8):1323-1343. doi: 10.4161/onci.22009.

Ladányi A. Prognostic and predictive significance of immune cells infiltrating

cutaneous melanoma. Vol. 28, Pigment Cell and Melanoma Research.

28 (5) p. 490–500. doi: 10.1111/pcmr.12371.

Yu J, Wu X, Yu H, Li S, Mao LL, Chi Z, et al. Systemic Immune-

Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes

in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon.

Transl Oncol. 2017;10(5):719–25. doi: 10.1016/j.tranon.2017.06.004.

Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, et al. Ipilimumab real-

world efficacy and safety in Korean melanoma patients from the Korean

named-patient program cohort. Cancer Res Treat. 2017;49(1):44–53. doi:

4143/crt.2016.024.

Lee J, Lee SJ, Kim K, Kim ST, Jang KT, Lee J. Comprehensive molecular

and clinical characterization of Asian melanoma patients treated with anti-

PD-1 antibody. BMC Cancer. 2019;19(1):1–7. doi: 10.1186/s12885-019-

-5.

Impact of Neutrophil-Lymphocyte Ratio in Acral Lentiginous melanoma